Pittsburgh Alliance, Amazon drive AI product development in Steel City

Dave Pearson | | Health Exec | Precision Medicine
Pittsburgh

A large health data-sharing consortium based in Pittsburgh is bringing in Amazon Web Services to help drive research and product development around machine learning and cloud computing in numerous areas of healthcare.

The Pittsburgh Health Data Alliance (PHDA) announced the arrangement Aug. 7, saying scientists from PHDA member institutions—namely the University of Pittsburgh and Carnegie Mellon—will leverage AWS support to accelerate AI activity in cancer risk scoring, mental healthcare, diagnostic accuracy and other concentrations.

For example, a research team led by U of Pitt bioengineer David Vorp, PhD, is developing an algorithm that will guide surgeries for abdominal aortic aneurysms performed before symptoms show up.

The PHDA’s membership also includes the 40-hospital UPMC integrated health system.

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Design by Adaptive Theme
Trimed Popup
Trimed Popup